Live feed07:00:00·13mPRReleasevia QuantisnowSingle infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myelomaByQuantisnow·Wall Street's wire, on your screen.JNJ· Johnson & JohnsonHealth Care
